TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer: Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI

Autor: Kibel, Adam S.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2007 25(5):448-448

Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer: Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA, Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI. J Natl Cancer Inst 2003;95:661–668

Autor: Chatta, Gurkamal

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2003 21(6):488-488

Re: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer - Tomlins SA, Rhodes DR, Perrier S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chirmaiyan AM

Publikováno v: European Urology. 51(5):1443-1444

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::c596e25d779b4e9b7c2783437477373a

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.

Autor: Bulen BJ; Strata Oncology, Ann Arbor, Michigan., Khazanov NA; Strata Oncology, Ann Arbor, Michigan., Hovelson DH; Strata Oncology, Ann Arbor, Michigan., Lamb LE; Strata Oncology, Ann Arbor, Michigan., Matrana M; Ochsner Cancer Institute, New Orleans, Louisiana., Burkard ME; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Yang ES; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama., Edenfield WJ; Prisma Health Greenville Memorial Hospital, Greenville, Carolina., Claire Dees E; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina., Onitilo AA; Cancer Care and Research Center, Marshfield Clinic Research Institute, Marshfield, Wisconsin., Buchschacher GL; Kaiser Permanente Southern California, Los Angeles, California., Miller AM; Translational Drug Development, Scottsdale, Arizona., Parsons BM; Gundersen Health System, La Crosse, Wisconsin., Wassenaar TR; UW Health Cancer Center at ProHealth Care, Waukesha, Wisconsin., Suga JM; Kaiser Permanente Northern California, Vallejo, California., Siegel RD; Bon Secours St. Francis Cancer Center, Greenville, Carolina., Irvin W; Bon Secours Cancer Institute, Midlothian, Virginia., Nair S; Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania., Slim JN; MultiCare Regional Cancer Center - Tacoma, Washington., Misleh J; The US Oncology Network, Newark, Delaware., Khatri J; ChristianaCare Oncology Hematology, Newark, Delaware., Masters GA; Medical Oncology Hematology Consultants, Helen F Graham Cancer Center and Research Institute, Newark, Delaware., Thomas S; Kaiser Permanente Northern California, Oakland, California., Safa MM; Kettering Health, Kettering, Ohio., Anderson DM; Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, Minnesota., Mowers J; Strata Oncology, Ann Arbor, Michigan., Dusenbery AC; Strata Oncology, Ann Arbor, Michigan., Drewery S; Strata Oncology, Ann Arbor, Michigan., Plouffe K; Strata Oncology, Ann Arbor, Michigan., Reeder T; Strata Oncology, Ann Arbor, Michigan., Vakil H; Strata Oncology, Ann Arbor, Michigan., Patrias L; Strata Oncology, Ann Arbor, Michigan., Falzetta A; Strata Oncology, Ann Arbor, Michigan., Hamilton R; Strata Oncology, Ann Arbor, Michigan., Kwiatkowski K; Strata Oncology, Ann Arbor, Michigan., Johnson DB; Strata Oncology, Ann Arbor, Michigan., Rhodes DR; Strata Oncology, Ann Arbor, Michigan., Tomlins SA; Strata Oncology, Ann Arbor, Michigan.

Publikováno v: Cancer research communications [Cancer Res Commun] 2023 Jul 25; Vol. 3 (7), pp. 1335-1349. Date of Electronic Publication: 2023 Jul 25 (Print Publication: 2023).

Comprehensive genomic profiling of 30,000 consecutive solid tumors

Autor: Gonzalez A, Elizabeth Claire Dees, Rhodes Dr, Kellum A, Kwiatkowski K, Hovelson Dh, Drewery S, Guarino M, Edenfield Wj, Leon Christopher Hwang, de la Vega Ll, Siegel R, Scott A. Tomlins, Mitchell K, Johnson Db, Suresh G. Nair Md, Adedayo A. Onitilo, Reeder T, Malek M. Safa, Falkner J, Wassenaar T, Javed Siddiqui, Miller A, Vakil H, Harish, Eddy S. Yang, Han A. Koh, Michael A. Thompson, McNulty B, Benjamin M. Parsons, Mark E. Burkard, Hipp J, Jennifer Marie Suga, Slim Jn, Irvin Wj, Anderson Dm, W. Schulz, Fischer A, Alex R. Menter, Arvinda Padmanabhan, Jamil Khatri, Mansoor Ah, Matrana Mr, Paul W. Harms

PurposeTissue-based comprehensive genomic profiling (CGP) is increasingly utilized for treatment selection in patients with advanced solid tumors, however real-world tissue availability may limit widespread implementation. Here we established real-wo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3edd87bbccb65230dd46eaaec792e554
https://doi.org/10.1101/2020.11.19.20233866